ImpediMed Limited (ASX:IPD)
0.0040
0.00 (0.00%)
Nov 17, 2026, 10:25 AM AEDT
ImpediMed Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, ImpediMed stock has a consensus rating of "Buy" and an average price target of $0.02. The average 1-year stock price forecast is 388.50% higher than the current stock price, while the lowest is $0.01 (+115.75%) and the highest is $0.04 (+900.00%).
Price Target: $0.02 (+388.50%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for ImpediMed stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | May '26 | Jul '26 | Aug '26 | Sep '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 2 | 2 | 1 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bell Potter | Bell Potter | Buy Maintains $0.01 | Buy | Maintains | $0.01 | +150.00% | Nov 1, 2026 |
| Morgans | Morgans | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | Aug 31, 2026 |
Financial Forecast
Revenue This Year
19.31M
from 14.61M
Increased by 32.11%
Revenue Next Year
25.75M
from 19.31M
Increased by 33.37%
EPS This Year
-0.00
from -0.01
EPS Next Year
-0.00
from -0.00
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.